Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1992-11

AUTHORS

Stephanie Green, Geoffrey R. Weiss

ABSTRACT

The Southwest Oncology Group, in cooperation with the National Cancer Institute and the other major cooperative oncology groups, has participated in the development of new toxicity criteria for reporting the results of cancer clinical trials. The new criteria (NCI Common Toxicity Criteria) respond to a recognized need to: (1) report toxicities consistently among cooperative groups, particularly for shared 'intergroup' clinical trials; (2) strive for comparability in toxicity reporting among clinical trials; and (3) recognize new toxicities accompanying new classes of anticancer treatment modalities. The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. In addition, endpoint definitions and response criteria are discussed. These have been developed in response to previous uncertainties in clinical trials objectives, to limitations in the resolution of imaging methods, and to demands for greater rigor in response and endpoint definitions. Toxicity criteria, endpoint definitions, and response criteria are tabulated. More... »

PAGES

239-253

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00944177

DOI

http://dx.doi.org/10.1007/bf00944177

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017722235

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1487397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Southwest Oncology Group Statistical Center, 1124 Columbia Street, 98104, Seattle, Washington, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Green", 
        "givenName": "Stephanie", 
        "id": "sg:person.014014114517.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014014114517.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Health Science Center at San Antonio", 
          "id": "https://www.grid.ac/institutes/grid.267309.9", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78284, San Antonio, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weiss", 
        "givenName": "Geoffrey R.", 
        "id": "sg:person.013747706762.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013747706762.64"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1992-11", 
    "datePublishedReg": "1992-11-01", 
    "description": "The Southwest Oncology Group, in cooperation with the National Cancer Institute and the other major cooperative oncology groups, has participated in the development of new toxicity criteria for reporting the results of cancer clinical trials. The new criteria (NCI Common Toxicity Criteria) respond to a recognized need to: (1) report toxicities consistently among cooperative groups, particularly for shared 'intergroup' clinical trials; (2) strive for comparability in toxicity reporting among clinical trials; and (3) recognize new toxicities accompanying new classes of anticancer treatment modalities. The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. In addition, endpoint definitions and response criteria are discussed. These have been developed in response to previous uncertainties in clinical trials objectives, to limitations in the resolution of imaging methods, and to demands for greater rigor in response and endpoint definitions. Toxicity criteria, endpoint definitions, and response criteria are tabulated.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00944177", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2693350", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693495", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria", 
    "pagination": "239-253", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "547088923206db72ea270af3fc011f75572ea32adb31ba3546ae1fc0cf2cb72c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1487397"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00944177"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017722235"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00944177", 
      "https://app.dimensions.ai/details/publication/pub.1017722235"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000487.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00944177"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'


 

This table displays all metadata directly associated to this object as RDF triples.

103 TRIPLES      20 PREDICATES      34 URIs      26 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00944177 schema:about N75aae0db2b6244eebf92da4c825a51c0
2 N83bb4d8ce95c4ed990e603332b5e2a35
3 N90498df080864762a3be8a3b26b75d01
4 Nb7310f87322f4e248443f0f6e11cda0b
5 Nfd3828673f8e4482b81d440109ef8560
6 anzsrc-for:11
7 anzsrc-for:1112
8 schema:author N6774242225834798b993ecd1eb89ccd7
9 schema:datePublished 1992-11
10 schema:datePublishedReg 1992-11-01
11 schema:description The Southwest Oncology Group, in cooperation with the National Cancer Institute and the other major cooperative oncology groups, has participated in the development of new toxicity criteria for reporting the results of cancer clinical trials. The new criteria (NCI Common Toxicity Criteria) respond to a recognized need to: (1) report toxicities consistently among cooperative groups, particularly for shared 'intergroup' clinical trials; (2) strive for comparability in toxicity reporting among clinical trials; and (3) recognize new toxicities accompanying new classes of anticancer treatment modalities. The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. In addition, endpoint definitions and response criteria are discussed. These have been developed in response to previous uncertainties in clinical trials objectives, to limitations in the resolution of imaging methods, and to demands for greater rigor in response and endpoint definitions. Toxicity criteria, endpoint definitions, and response criteria are tabulated.
12 schema:genre research_article
13 schema:inLanguage en
14 schema:isAccessibleForFree false
15 schema:isPartOf N1ed9d0a441db4653a67ddda4eac69d50
16 Nf57803fad3d2495485e3e88f47ef0c4d
17 sg:journal.1094201
18 schema:name Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
19 schema:pagination 239-253
20 schema:productId N0590eb78ed07409dbc25758abbb09480
21 N33f69377c4ad46338f59d69f958d883e
22 N7b06e3b2bf3243aaa38af794e37064b2
23 N803d2523a6c64fa1a59ccd2288771a81
24 Nebb9d0b08cff49b0a85c7289a2ec4d41
25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017722235
26 https://doi.org/10.1007/bf00944177
27 schema:sdDatePublished 2019-04-10T15:45
28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
29 schema:sdPublisher Ne769eb52e1914c308bbcde5d7d273dfe
30 schema:url http://link.springer.com/10.1007/BF00944177
31 sgo:license sg:explorer/license/
32 sgo:sdDataset articles
33 rdf:type schema:ScholarlyArticle
34 N0590eb78ed07409dbc25758abbb09480 schema:name doi
35 schema:value 10.1007/bf00944177
36 rdf:type schema:PropertyValue
37 N1ed9d0a441db4653a67ddda4eac69d50 schema:volumeNumber 10
38 rdf:type schema:PublicationVolume
39 N33f69377c4ad46338f59d69f958d883e schema:name nlm_unique_id
40 schema:value 8309330
41 rdf:type schema:PropertyValue
42 N6774242225834798b993ecd1eb89ccd7 rdf:first sg:person.014014114517.46
43 rdf:rest Nd496a95eaa3f4fdc90757323803d068e
44 N75aae0db2b6244eebf92da4c825a51c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
45 schema:name Neoplasms
46 rdf:type schema:DefinedTerm
47 N7b06e3b2bf3243aaa38af794e37064b2 schema:name readcube_id
48 schema:value 547088923206db72ea270af3fc011f75572ea32adb31ba3546ae1fc0cf2cb72c
49 rdf:type schema:PropertyValue
50 N803d2523a6c64fa1a59ccd2288771a81 schema:name pubmed_id
51 schema:value 1487397
52 rdf:type schema:PropertyValue
53 N83bb4d8ce95c4ed990e603332b5e2a35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Humans
55 rdf:type schema:DefinedTerm
56 N90498df080864762a3be8a3b26b75d01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Remission Induction
58 rdf:type schema:DefinedTerm
59 Nb7310f87322f4e248443f0f6e11cda0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Combined Modality Therapy
61 rdf:type schema:DefinedTerm
62 Nd496a95eaa3f4fdc90757323803d068e rdf:first sg:person.013747706762.64
63 rdf:rest rdf:nil
64 Ne769eb52e1914c308bbcde5d7d273dfe schema:name Springer Nature - SN SciGraph project
65 rdf:type schema:Organization
66 Nebb9d0b08cff49b0a85c7289a2ec4d41 schema:name dimensions_id
67 schema:value pub.1017722235
68 rdf:type schema:PropertyValue
69 Nf57803fad3d2495485e3e88f47ef0c4d schema:issueNumber 4
70 rdf:type schema:PublicationIssue
71 Nfd3828673f8e4482b81d440109ef8560 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Treatment Outcome
73 rdf:type schema:DefinedTerm
74 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
75 schema:name Medical and Health Sciences
76 rdf:type schema:DefinedTerm
77 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
78 schema:name Oncology and Carcinogenesis
79 rdf:type schema:DefinedTerm
80 sg:grant.2693350 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00944177
81 rdf:type schema:MonetaryGrant
82 sg:grant.2693495 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00944177
83 rdf:type schema:MonetaryGrant
84 sg:journal.1094201 schema:issn 0167-6997
85 1573-0646
86 schema:name Investigational New Drugs
87 rdf:type schema:Periodical
88 sg:person.013747706762.64 schema:affiliation https://www.grid.ac/institutes/grid.267309.9
89 schema:familyName Weiss
90 schema:givenName Geoffrey R.
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013747706762.64
92 rdf:type schema:Person
93 sg:person.014014114517.46 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
94 schema:familyName Green
95 schema:givenName Stephanie
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014014114517.46
97 rdf:type schema:Person
98 https://www.grid.ac/institutes/grid.267309.9 schema:alternateName The University of Texas Health Science Center at San Antonio
99 schema:name Department of Medicine, Division of Medical Oncology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78284, San Antonio, Texas, USA
100 rdf:type schema:Organization
101 https://www.grid.ac/institutes/grid.48336.3a schema:alternateName National Cancer Institute
102 schema:name Southwest Oncology Group Statistical Center, 1124 Columbia Street, 98104, Seattle, Washington, USA
103 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...